Kai He, MD, PhD
Dr. Kai He is an innovative medical oncologist who specializes in the care of lung cancer and malignant pleural mesothelioma patients at the James Cancer Hospital of The Ohio State University. Dr. He’s expertise lies in providing personalized care based on his patients’ unique clinical, genetic, and immunological characteristics.[1]
Dr. He is also a physician-scientist within Ohio State University Comprehensive Cancer Center’s Translational Therapeutics Program, where he focuses on cancer epigenetics, genomics and immunology, and their associated novel biomarker and therapeutic development in treating lung cancer and other thoracic malignancies.
Education and Career
Dr. He attended medical school at the Peking Union Medical College in Beijing and continued there for his internship in Internal Medicine. He followed this stage in his education by earning a Ph.D. in Cell Biology at the University of Alabama at Birmingham, then went on to an internship in Internal Medicine and Residency at the North Shore Long Island Jewish. Dr. He finished his education by completing clinical and research fellowships in Medical Oncology at Johns Hopkins Hospital, where he was awarded a T32 training grant for studying epigenetics and cancer immunity in lung cancer.[1]
Dr. He remained at Johns Hopkins as a member of the Medical Oncology faculty at the Sidney Kimmel Comprehensive Cancer Center and the Johns Hopkins School of Medicine, then joined the faculty at Ohio State University’s Wexner School of Medicine and began practicing as part of the thoracic oncology program at James Cancer Hospital.
Research
Dr. He’s laboratory studies the determinants for the response and resistance to immunotherapy in lung cancer, from the genomic instability and tumor mutation-related neoantigen to the dynamic immune landscape evolution related to immunotherapy. He has co-authored over 30 articles published in peer-reviewed journals, including Cancer Discovery, Journal of Thoracic Oncology, Clinical Lung Cancer, and Journal of Hematology & Oncology. He also serves as an ad hoc reviewer for many journals and is a member of the Pelotonia Institute for Immuno-Oncology and the James Cancer Center Clinical Scientific Review Committee.[1]
